The RITUXAN for RA EXPERIENCE Program

 

through Genentech
Rheumatology
Access Solutions

$4,000 per
12-month period
toward the cost of
Rituxan for eligible patients

Learn More

Indication

Rituxan® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

Important Safety Information

RITUXAN administration can result in serious, including fatal, adverse reactions. These include: infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy (PML).

Warnings and Precautions

Rituxan administration can also result in additional serious, including fatal, adverse reactions including:

  • hepatitis B reactivation
  • other infections including bacterial, fungal, new or reactivated viral infections
  • cardiovascular events

Patients should be closely observed for signs of infection if biologic agents and /or DMARDs other than methotrexate are used concomitantly

Common adverse reactions include infusion reactions and infections

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

Print Page
 

Rituxan is approved for retreatment at 6-month intervals

Patients can be effectively retreated every 6 months before signs and symptoms reappear1

Retreatment chart
  • Each course is administered as two 1000-mg IV infusions separated by 2 weeks
  • Subsequent courses should be administered every 24 weeks or based on physician evaluation, but not sooner than every 16 weeks1
 
Reference
1.
Rituxan [package insert]. South San Francisco, CA: Biogen Idec Inc. and Genentech USA, Inc.; February 2010.